Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

vortioxetine

Bristol-Myers Squibb (BMS) building

BMS gets two new cancer approvals in Europe

Empliciti, and Opdivo and Yervoy inhibitor combination get the green light

- PMLiVE

Cell Therapy licenses heart failure therapy in Japan

EMA may grant Welsh-based biotech a marketing application in mid-2016

Bristol Myers Squibb logo

Opdivo edges closer to first haematological cancer indication

EMA begins review of BMS' classic Hodgkin’s lymphoma inhibitor treatment

- PMLiVE

EMA starts review of Gilead’s Zydelig on ‘serious’ safety concerns

Trials of the leukaemia treatment have been halted while the investigation is underway

EU flag

EMA initiative aims to fast-track important new drugs

Hopes PRIME programme will foster greater cooperation with industry 

- PMLiVE

The EMA’s literature screening service and pharma

Complexities and new potential in pharmacovigilance

dengue fever mosquito

EMA creates Zika virus task force

Will aid research and development of vaccines and medicines

Digital roundup

Genzyme, Merck, the forthcoming EU clinical trials portal and more

- PMLiVE

AstraZeneca wins European approval for Tagrisso

The first-in-class lung cancer treatment receives a conditional licence

EU flag

EMA unveils draft guidelines for Alzheimer’s disease research

Puts plans for evaluating potential new therapies out for consultation

- PMLiVE

Alkermes depression drug misses targets in phase III

Irish firm suffers major research setback with ALKS 5461

- PMLiVE

Bayer defends Xarelto as pivotal trial scrutinised

ROCKET AF trial results questioned after some INRATIO devices used in testing recalled

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links